History

Rodos BioTarget GmbH (RBT) emanated as a start-up from the non-profit Let There Be Hope Medical Research Institute in Beverly Hills, California. One major focus of this organization was to devise and develop novel treatments for HIV/AIDS. These investigations led to technologies for addressing intact infectious HIV within certain reservoir cells. However, it became soon apparent that these technologies actually represent platforms whose potentials may extend far beyond HIV/AIDS. Related patent applications were then submitted in the USA, the EU, Japan, and Canada. Once founded in Hannover, Germany, by some of the inventors, RBT purchased the IP. In 2007, RBT received three business plan prizes and awards.

Within the first year after inception, RBT’s developmental lead indication remained to be HIV/AIDS. However, due to additional highly promising data on HCV/Hepatitis C, as well as the even greater epidemiological impact of chronic hepatitis C and its sequelae - such as hepatocellular carcinoma - this viral disease is now RBT’s lead indication. Moreover, we have recognized that our technologies may also enable multiple additional disease-protective and therapeutic purposes. As a result, RBT’s development pipeline currently comprises TargoSphere^®-delivered treatments for eradicating cellular viral reservoirs in HCV/Hepatitis C and other viral infections as well as TargoSphere^®-dependent vaccination approaches for various cancers as well as malaria, in which novel cancer and malaria protein vaccines are administered. Furthermore, RBT has successfully completed a pilot study in the area of specific immunotherapy for treating allergic diseases.